Posters & Presentations

February 2023

Fourth Annual HCC-TAG Conference

Huntington Beach, CA

• How Measuring Liver Function Can Aid Clinical Management of Hepatocellular Carcinoma

November 2022

Obesity & NASH Drug Development Summit

Boston, MA

• Moving the Needle (Literally) in Drug Development

November 2022

AASLD – The Liver Meeting 2022

• Compartmental Modeling Enhances the Reliability of the Measurement of Portal Systemic Shunting by the HepQuant SHUNT Test
• HepQuant SHUNT is Superior to Child-Pugh in Defining Hepatic Impairment for Pharmacokinetic Studies: Experience With Ampreloxetine

September 2022

The American College of Clinical Pharmacology® (ACCP) Annual Meeting

Bethesda, MD

• Advantages of HepQuant SHUNT over Child-Pugh Classification in Defining Hepatic Impairment for Pharmacokinetics Studies: Experience with Ampreloxetine

June 2022

EASL International Liver Congress™ 2022

London, UK

• A multi-compartmental model of the HepQuant SHUNT test quantifies anatomic shunting and stratifies risk for varices: combined results from the HALT-C and SHUNT-V studies

May 2022

Digestive Disease Week DDW® 2022

San Diego, CA

• The HepQuant Shunt Disease Severity Index (HepQuant DSI™) Can Aid the Decision to Avoid Endoscopic Screening or Surveillance for Varices Needing Treatment

November 2021

AASLD The Liver Meeting

• BI 685509 Improves Hepatic Function in Subjects with Child-Pugh A Cirrhosis and a Liver Stiffness Measurement of >15 KPA: Results from the HepQuant SHUNT Test. Lawitz EJ, Ertle J, Schoelch C, Gawshaw I, Helmke SM and Everson GT. {Lawitz et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1238A-1239A}
• The HepQuant SHUNT Test Predicts the Likelihood of Finding Esophageal Varices and Particularly Large Varices at Endoscopy. Shiffman ML, Leise MD, Reddy KR, Hellstern PA, Hassanein T, Qureshi K, Mena E, Smith AD, Kittelson JM, Helmke SM, Everson GT, HepQuant, and SHUNT-V Investigators Group. {Shiffman et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1264A-1265A}
• Oral presentation: Treatment with HMG-CoA Reductase Inhibitors (Statins) is Associated with Preservation of Hepatic Function in Advanced Chronic Liver Disease (CLD): Results from the SHUNT-V Study. Rahimi RS, Lucas KJ, Weinberg EM, Kayali Z, Bhagat VK, Keaveny AP, Mantry PS, Smith AD, Kittelson JM, Helmke SM, Everson GT, and SHUNT-V Investigators Group. {Rahimi et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 98A-99A}